Protagonist Therapeutics (PTGX)
(Delayed Data from NSDQ)
$28.23 USD
-0.04 (-0.14%)
Updated May 10, 2024 04:00 PM ET
After-Market: $28.24 +0.01 (0.04%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth C Momentum F VGM
Brokerage Reports
Protagonist Therapeutics, Inc. [PTGX]
Reports for Purchase
Showing records 41 - 49 ( 49 total )
Company: Protagonist Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Early Phase 2 Results Make Polycythemia Vera the Focus for PTG-300
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Protagonist Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Some Patience Is Needed, But Three Assets Moving Towards Phase 3
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Protagonist Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
PD Data Robust; But We Still Await Clinical Proof of Concept
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Protagonist Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Let''s Not Jump to Conclusions on PTG-300; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Protagonist Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Protagonist Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Takeaways From Our Coverage at the Global Investment Conference
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Protagonist Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Protagonist Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
PN-943 Continues to Look Promising; Reiterating Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D